News Releases Year: All News201920182017201620152014 Items per page All News2550 Summary ToggleHepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference Summary Toggle September 4, 2019 View News Release > Summary ToggleHepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Summary Toggle September 3, 2019 View News Release > Summary ToggleHepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 Summary Toggle August 14, 2019 View News Release > Summary ToggleHepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board Summary Toggle August 7, 2019 View News Release > Summary ToggleHepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta Summary Toggle July 31, 2019 View News Release > Summary ToggleHepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH Summary Toggle July 29, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA” Summary Toggle July 22, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH Summary Toggle June 27, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH Summary Toggle June 20, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering Summary Toggle June 18, 2019 View News Release > Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
